Pēdējā atjaunošana :
19/11/2024
vēzis narkotiku   Mitoxantrone dihydrochloride  
Injekcija
Šķīduma stabilitāte Maisījuma stabilitāte Stabilitāti ietekmējoši faktori Saderība Levadīšanas veids Literatūras saraksts pdf
   Ķīmiskā uzbūve   

Oriģinālais nosaukums   Oriģinālais nosaukums     

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Bluxantron Ekvadora
Bresnix Meksika
Ebexantron Austrija
Elsep Francija
Formyxan Ekvadora, Kolumbija, Meksika
Genefadrone Grieķija
Mitoxgen Argentīna
Neotalem Meksika
Novantron Austrija, Šveice, Vācija
Novantrone Amerikas Savienotās Valstis, Apvienotie Arābu Emirāti, Beļģija, Čīle, Dānija, Dienvidāfrikas Republika, Francija, Grieķija, Īrija, Itālija, Jaunzēlande, Luksemburga, Malaizija, Maroka, Norvēģija, Rumānija, Slovēnija, Spānija, Taizeme, Turcija, Ungārija, Zviedrija
Onkotrone Austrālija, Itālija, Lielbritānija, Luksemburga, Rumānija, Vācija
Ralenova Vācija
Refador Ungārija
Santrone Ēģipte, Malaizija
Strimax Spānija
Xantrosin Beļģija
Literatūras saraksts   Injekcija   Literatūras saraksts : Mitoxantrone dihydrochloride  
tips publicēšana
3 Žurnāls Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Žurnāls Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Žurnāls Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Žurnāls Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Žurnāls Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Žurnāls Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Žurnāls Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Žurnāls Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Žurnāls Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Žurnāls Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Žurnāls Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Žurnāls Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Žurnāls Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Žurnāls Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Žurnāls Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
484 Žurnāls Northcott M, Allsopp MA, Powell H, Sewell GJ.
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
J Clin Pharm Ther 1991 ; 16: 123-129.
492 Žurnāls Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
828 Žurnāls Lecompte D, Bousselet M, Magnam J.
Stability of mitoxantrone (Novantrone*) after dilution in PVC infusions.
J Pharm Clin 1990 ; 9: 159-165.
905 Žurnāls Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Žurnāls Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1317 Žurnāls Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG.
Pharmaceutical aspects of home infusion therapy for cancer patients.
Pharm J 1987 ; 238: 476-478.
1410 Žurnāls Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Žurnāls Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Žurnāls Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Žurnāls Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Žurnāls Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Žurnāls Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1730 Žurnāls Björkman S, Roth B.
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Act Pharm Nord 1991 ; 3: 251.
1925 Žurnāls Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Žurnāls Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2344 Laboratorija Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3640 Laboratorija Mitoxantrone - Summary of Product Characteristics
Hospira 2013

  Mentions Légales